Skip to main content

Table 3 Summary of studies of recurrence patterns of glioblastoma in the temozolomide era

From: Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution

Author

Clinical target delineation and prescribed dose

Analyzed recurrent patients

Proportion of central recurrence

(year)

CTV1 (initial field)

CTV2 (boost field)

Brandes et al. [6]

Enhanced tumor area according to preoperative imaging plus 2–3 cm

None (identical with initial field)

79

72.2%a

60 Gy in 30 fractions

Milano et al. [7]

Edema plus 2 cm

Residual tumor/resection cavity plus 2–2.5 cm

39

80%b

46–50 Gy in 23–25 fractions

60 Gy in 30 fractions

Minniti et al. [8]

Residual tumor/resection cavity plus 2 cm

Residual tumor/resection cavity plus 1–2 cm

105

75.2%c

50 Gy in 25 fractions

60 Gy in 30 fractions

McDonald et al. [9]

Edema plus 0.5–1.2 cm

Residual tumor/resection cavity plus 0–1 cm

41

78%d

46–54 Gy in 23–30 fractions

60 Gy in 30 fractions

Dobelbower et al. [10]

Primary tumor and surrounding edema plus 0.5 cm on postoperative imaging

Residual tumor/resection cavity plus 0.5 cm

20

90%a

60Gy in 30 fractions

46 Gy in 23 fractions

Present Study

Residual tumor/resection cavity plus 2 cm and edema

Residual tumor/resection cavity plus 0 cm

21

66.7%

50–54 Gy in 25–30 fractions

60 Gy in 30 fractions

  1. CTV: clinical target volume.
  2. aThe term “central” was not actually used in the report. Instead, “in-field” recurrence was defined as 80% of the tumor recurrence residing within the prescribed 95% isodose surface.
  3. bCentral recurrence was defined as growth of the original tumor or arising tumor(s) from the resection cavity.
  4. cCentral recurrence was defined as more than 95% of the recurrence volume within the 95% isodose line of 60 Gy.
  5. dCentral recurrence was defined as more than 95% of the recurrence volume inside the 100% isodose line of 60 Gy.